Navigation Links
FDA Puts Partial Hold on Avandia Safety Study
Date:7/21/2010

WEDNESDAY, July 21 (HealthDay News) -- No new patients will be permitted to enroll in a safety study of the controversial diabetes drug Avandia until further notice, the U.S. Food and Drug Administration announced Wednesday.

But under the partial clinical trial hold, those patients already enrolled in the TIDE (Thiazolidinedione Intervention With Vitamin D Evaluation) trial will be allowed to continue to participate, the agency said in a news release.

An FDA advisory panel last week ruled that Avandia (rosiglitazone) does boost users' heart risks, but it also decided that the drug should stay on the market because there's no definitive evidence of an increased risk.

The FDA said Wednesday that it is evaluating available data on Avandia's safety and the discussions from last week's advisory panel meeting. When the review is complete, the agency will inform the public about the findings and what they mean for the drug's status and the TIDE trial.

GlaxoSmithKline, which makes Avandia, was told by the FDA to update researchers, institutional review boards and ethics committees involved in the TIDE trial about new safety information presented at the FDA advisory panel meeting. That information can be used to update informed consent information for people already enrolled in the TIDE trial, the FDA said.

GSK agreed to conduct the TIDE trial in 2007 after concerns about the safety of Avandia first became public. The goal of the trial is to determine whether Avandia poses greater heart risks than a competing drug called Actos.

In a news release, the drug company confirmed that it will suspend enrollment of new patients in the TIDE trial and send a summary of recent safety data and a summary of the FDA advisory panel meeting to all TIDE researchers and institutional review boards.

"This pause in enrollment will give clinical trial investigators and patients time to learn about the data presented to the FDA Advisory Committee and the Committee's recommendations," Dr. Ellen Strahlman, GSK's chief medical officer, said in the news release.

"Patients with questions about the use of Avandia should talk with their physicians," she added.

More information

The U.S. National Library of Medicine has more about rosiglitazone.

-- Robert Preidt

SOURCES: U.S. Food and Drug Administration and GlaxoSmithKline, news releases, July 21, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Lacosamide validated as promising therapy for uncontrolled partial-onset seizures
2. Deep brain stimulation reduces epileptic seizures in patients with refractory partial and secondarily generalized seizures
3. Study shows partial lung removal favorable over full removal as treatment for lung cancer
4. Hip surgery success partially predicted by number of other existing conditions
5. Diabetes Drugs Avandia, Actos Tied to Fractures in Women
6. Remove Diabetes Drug Avandia From Market: FDA Reports
7. Remove Diabetes Drug Avandia From Market: FDA Documents
8. FDA Says It Hasnt Decided Whether to Pull Diabetes Drug Avandia Off the Market
9. FDA: No Decision on Whether to Pull Diabetes Drug Avandia Off the Market
10. Maher Law Firm Warns Avandia Users - NY Times Reports - FDA Recommends Recall of Avandia
11. Diabetes Drug Avandia Ups Heart Risk, Reviews Conclude
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Puts Partial Hold on Avandia Safety Study
(Date:10/13/2017)... Rock, AR (PRWEB) , ... October 13, 2017 ... ... firm with locations throughout Arkansas that offers insurance and financial preparation services, is ... benefit the Rock City Rescue organization. , Rock City Rescue is a locally ...
(Date:10/13/2017)... ... , ... PurhealthRX , a leading Health and Nutrition Company, is announcing ... full spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the ... incorporated into liquid products, while reducing costs to end users. , The team of ...
(Date:10/13/2017)... ... 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills is ... vendors and unique items from across the nation, this holiday-themed event will raise funds ... by the VNA. The boutique will be open Saturday, November 4 (10:00 a.m. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/12/2017)... ... , ... Planet Fitness, one of the largest and fastest growing franchisors and ... flagship location in Covington, LA at 401 N. U.S. Highway 190, in January of ... Depot in the Holiday Square shopping center. Its location allows it to serve both ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
(Date:9/19/2017)... 2017   ZirMed Inc ., a recognized leader in ... it has been ranked #1 by its users for the ... 2017 User Survey. ZirMed was recognized as the top-ranked end-to-end ... medical centers over 200 beds and holds one of the ... survey history. ...
(Date:9/12/2017)... -- Consumer reviews on the independent review site Consumer Affairs ... for hearing aids, ranking it higher than Miracle Ear ™, ... ... Hearing Aids ... store that provides high performance, state-of-the-art, German-engineered hearing aids directly to ...
Breaking Medicine Technology: